FDA Approves Breast Cancer Drug Veppanu for ER+ Patients

On May 1st, the FDA approved Veppanu (bepedegertrant) for treating advanced and metastatic ER+/HER2- breast cancer with ESR1 mutations. On April 30th, the agency also cleared the first non-psychiatric medication for agitation in dementia, accelerating the oncology and neurology drug pipeline.